Cyclic endomorphin analogs in targeting opioid receptors to achieve pain relief. (December 2014)

• Record Type: Journal Article
• Authors: Janecka, Anna; Gentilucci, Luca
• Is Part Of: Future medicinal chemistry. Volume 6:Number 18(2014)
• Page Start: 2093
• Page End: 2101
• Publication Date: 2014-12
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.4155/fmc.14.132
• Languages: English
• ISSNs: 1756-8919

Abstract

Endomorphins, the endogenous ligands of the µ-opioid receptor, are attractive candidates for opioid-based pain-relieving agents. These tetrapeptides, with their remarkable affinity for the µ-opioid receptor, display favorable antinociceptive activity when injected directly into the brain of experimental animals. However, the application of endomorphins as clinical analgesics has been impeded by their instability in body fluids and inability to reach the brain after systemic administration. Among numerous modifications of the endomorphin structure aimed at improving their pharmacological properties, cyclization can be viewed as an interesting option. Here, we have summarized recent advances in obtaining endomorphin-based cyclic peptide analogs